Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04042558
Title	A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)
Acronym	GFPC 06-2018
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Centre Francois Baclesse
Indications	lung non-squamous non-small cell carcinoma
Therapies	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Pemetrexed Disodium Atezolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Cisplatin + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	FRA